BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT) (OTC MARKETS: BNXTF) (FSE: BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. Mehr